Adding onartuzumab to erlotinib significantly shortened overall survival.
In nonmutated non–small-cell lung cancer (NSCLC), activation of the MET pathway has been identified as a possible mechanism of resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib. In a prior phase II study, combining erlotinib with the MET-targeting antibody onartuzumab improved survival in MET-positive NSCLC patients with disease progression after platinum-based chemotherapy (J Clin Oncol 2013; 31:4105).
To further test the combination of erlotinib and onartuzumab in this setting, investigators conducted an industry-supported, multicenter, randomized, double-blind, placebo-controlled, phase III trial (METLung), in which 499 pretreated patients with stage IIIB–IV locally advanced or metastatic …
Reviewing Author
DisclosuresConsultant/Advisory BoardGenentech; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Heron; Takeda; Ariad; MedIQ; Targeted Healthcare Communications; Novartis; OncLive; Roche; TRM Oncology
RoyaltiesUpToDate
Grant/Research SupportMedimmune; NIH/National Cancer Institute; Millennium; Genentech; Polaris Pharmaceuticals; Seattle Genetics; Boehringer-Ingelheim Pharmaceuticals; SWOG–Hope Foundation; American Cancer Society; Department of Defense; GlaxoSmithKline Pharmaceuticals; Merck; Eli Lilly; Takeda; Bristol-Myers Squibb
DisclosuresConsultant/Advisory BoardGenentech; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Heron; Takeda; Ariad; MedIQ; Targeted Healthcare Communications; Novartis; OncLive; Roche; TRM Oncology
RoyaltiesUpToDate
Grant/Research SupportMedimmune; NIH/National Cancer Institute; Millennium; Genentech; Polaris Pharmaceuticals; Seattle Genetics; Boehringer-Ingelheim Pharmaceuticals; SWOG–Hope Foundation; American Cancer Society; Department of Defense; GlaxoSmithKline Pharmaceuticals; Merck; Eli Lilly; Takeda; Bristol-Myers Squibb